

ASX RELEASE

20 September 2021

## DATE OF AGM AND CLOSING DATE FOR RECEIPT OF DIRECTOR NOMINATIONS

**Sydney, 20 September 2021** – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to advise that the Annual General Meeting of the Company will be held on **Wednesday 10 November 2021 at 10am Sydney time**. Further details will be provided to shareholders and released to ASX in due course, along with the Notice of Meeting.

In accordance with ASX listing rules, valid nominations for the position of director are required to be lodged at the registered office of the Company by **5.00 pm (AEST) on 29 September 2021**.

### About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immunology agents. A phase I study is expected to begin in CY2021.

For more information, please visit [www.kaziatherapeutics.com](http://www.kaziatherapeutics.com) or follow us on Twitter @KaziaTx. This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

### Board of Directors

**Mr Iain Ross** Chairman, Non-Executive Director

**Mr Bryce Carmine** Non-Executive Director

**Mr Steven Coffey** Non-Executive Director

**Dr James Garner** Chief Executive Officer, Managing Director